CA_(50)与CA_(19-9)联合检测对良恶性腹水鉴别诊断的价值  

MEASUREMENT OF CA_(50) AND CA_(19-9) THE VALUE OF DIFFERENTIAL DIAGNOSIS IN PATIENTS WITH BENIGN AND MALIGNANT ASCITES

作　　者：解祥军[1] 谢方瑜[1] 李清华[1] 张爱军[1] 

机构地区：[1]青岛市市立医院消化科,青岛266011

出　　处：《齐鲁医学杂志》2000年第3期173-174,共2页Medical Journal of Qilu

摘　　要：1目的　探讨糖类抗原 5 0 (CA5 0 )和糖类抗原 19- 9(CA1 9- 9)对良恶性腹水鉴别诊断的价值。 2方法分别测定良性和恶性腹水病人血清和腹水的 CA5 0 ,CA1 9- 9水平 ,用并联法评价多项肿瘤标志物联合应用对良恶性腹水的诊断价值。 3结果　 5 0例恶性腹水病人血清和腹水中 CA5 0 ,CA1 9- 9水平均显著高于良性腹水病人 (t=7.2 1～7.5 2 ,P<0 .0 1)。血清、腹水 CA5 0 和 CA1 9- 9联合检测对恶性腹水诊断的灵敏度达 94%和 92 % .4结论　 CA5 0 ,CA1 9- 9联合检测可使恶性腹水诊断的灵敏度明显增高 。Objective\ To evaluate CA 50 and CA 19 9 in the differential diagnosis of benign and malignant ascites.\ Methods\ Two tumor markers,CA 50 and CA 19 9 in ascites and serum were measured in 50 patients with malignant ascites and 50 patients with benign ascites.\ Results\ Ascites and serum levels of CA 50 and CA 19 9 in patients with malignant ascities were significantly higher than those in patients with benign ascites ( t=7.21-7.52,P <0.01).\ Conclusion\ Combination of two tumor markers increases sensitivity in diagnosis of benign and malignant ascites. [

关 键 词：良恶性腹水 鉴别诊断 CA50 CA19-9 

分 类 号：R730.53[医药卫生—肿瘤] R442.5[医药卫生—临床医学]